Scandion flunks phase 2 test just a month after exec departures
30 Sep 2022 //
FIERCEBIOTECH
Scandion Oncology receives approval for initiating the CORIST part 2 trial
06 Sep 2021 //
CISION
Scandion Oncology receives German trial approval for PANTAX Ib study
27 Aug 2021 //
CISION
Scandion Oncology announces results from the next evaluable chemo-resistant
21 Aug 2020 //
PRESS RELEASE
Scandion Oncology drug SCO-101 potentiates the effect of chemotherapy
31 Jul 2020 //
CISION
Clinical development plans for SCO-101
23 Mar 2020 //
CISION